none
Conditions
Interventions
observation group:3L of polyethylene glycol +linaclotide
control group:3L of polyethylene glycol
observation group:2L of polyethylene glycol + linaclotide
Sponsors
Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Three FC sets:Inclusion criteria for subjects: 1. Meet the Rome ? criteria for FC diagnosis, with a Wexner Constipation Scale (WCS) score of 17-25 points; 2. Aged 18-75, regardless of gender; 3. Patients undergoing routine or anesthesia colonoscopy; 4. Voluntarily participate and sign a written informed consent form. Three NC sets:Inclusion criteria for subjects: 1. Aged 18-75, regardless of gender; 2. Patients undergoing routine or anesthesia colonoscopy; 3. Voluntarily participate and sign a written informed consent form.
Exclusion criteria
Exclusion criteria: Three FC sets:1. History of serious heart, lung, liver, kidney diseases or cerebrovascular diseases within the past six months; 2. Clear history of colon polyps that have not been removed, colorectal cancer, or diarrhea (Bristol Stool Form Scale, BSFS stool consistency score of 6-7); 3. High-risk factors for intestinal preparation such as intestinal perforation, toxic megacolon, or intestinal obstruction; 4. Those who have taken laxatives, antidiarrheal medications, or other gastrointestinal motility drugs in the past two weeks; 5. History of gastrointestinal or pelvic surgery; 6. Pregnant and lactating women; 7. Allergy to the study drug. Three NC sets:1. A history of serious heart, lung, liver, kidney diseases, or cerebrovascular diseases within the past six months; 2. Clear history of constipation, colon polyps that have not been removed, colorectal cancer, or diarrhea (BSFS stool score of 6-7); 3. Risk factors for high-risk intestinal preparation, such as intestinal perforation, toxic megacolon, or intestinal obstruction; 4. Taking laxatives, anti-diarrheal drugs, or other gastrointestinal motility drugs in the past two weeks; 5. History of gastrointestinal or pelvic surgery; 6. Pregnant and lactating women; 7. Allergy to the study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bowel preparation therapy;Intestinal Preparation Compliance Rate;Incidence of adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| The detection rate of polyps;Cecal intubation rate;The detection rate of adenomas; | — |
Countries
China
Contacts
Public ContactZibin Tan
Affiliated Hospital of Qingdao University
Outcome results
None listed